Coronary stents: Novel developments

Heart

Volumn 100, Issue 13, 2014, Pages 1051-1061

  Stefanini, Giulio G ^a   Taniwaki, Masanori ^a   Windecker, Stephan ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHACRYLOYLOXYETHYLPHOSPHORYLCHOLINE; AMPHILIMUS; CHROMIUM; CHROMIUM DERIVATIVE; COBALT CHROMIUM; COPOLYMER; CYPHER; ETHYLENE VINYL ACETATE COPOLYMER; EVEROLIMUS; HYDROXYPROPYL METHACRYLATE; LACTONE; LAURYL METHACRYLATE; NOVOLIMUS; PACLITAXEL; PLATINUM CHROMIUM; POLY N BUTYL METHACRYLATE; POLYCAPROLACTONE; POLYGLACTIN; POLYGLYCOLIC ACID; POLYHEXYL METHACRYLATE; POLYLACTIC ACID; POLYMER; POLYVINYL ACETATE; POLYVINYL PYRROLIDINONE; RAPAMYCIN; STAINLESS STEEL; TRIMETHOXYSILYLPROPYL METHACRYLATE; UMIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINYLIDENE FLUORIDE HEXAFLUOROPROPYLENE COPOLYMER; ZOTAROLIMUS;

BARE METAL STENT; BIORESORBABLE SCAFFOLD; CONTROLLED DRUG RELEASE; CORONARY STENT; DRUG ELUTING STENT; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RISK REDUCTION; SELF EXPANDING STENT; STENT THROMBOSIS;

INTERVENTIONAL CARDIOLOGY;

ABSORBABLE IMPLANTS; ANIMALS; CARDIOVASCULAR AGENTS; DIFFUSION OF INNOVATION; DRUG-ELUTING STENTS; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; POLYMERS; PROSTHESIS DESIGN; TREATMENT OUTCOME;

EID: 84902360784     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-303522     Document Type: Review

References (20)

1. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med 2013;368:254-65.
2. Raber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial. Circulation 2011;123:2819-28.
3. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011;57:1314-22.
4. Raber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012;125:1110-21. ▶ Large scale cohort study showing a significant risk reduction of very late stent thrombosis with newer generation durable polymer everolimus eluting stents compared with early generation sirolimus eluting and paclitaxel eluting stents.
5. Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J 2012;33:1214-22. ▶ Individual patient data pooled analysis of three large scale trials providing evidence of improved safety (stent thrombosis) and efficacy (target lesion revascularisation) with biodegradable polymer drug eluting stents compared with early generation durable polymer sirolimus eluting stents.
6. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012;125:2873-91. ▶ Network meta-analysis indicating improved clinical outcomes with newer generation compared with early generation drug eluting stents.
7. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011;378:1940-8. ▶ Long term follow-up of an all-comer randomised trial demonstrating improved clinical outcomes with biodegradable polymer biolimus eluting stents compared with early generation durable polymer sirolimus eluting stents, primarily due to a significant risk reduction for very late stent thrombosis.
8. Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013;381:651-60.
9. Natsuaki M, Kozuma K, Morimoto T, et al. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol 2013;62:181-90. ▶ References 8 and 9 are two large scale randomised trials showing equivalent outcomes with biodegradable polymer biolimus eluting stents and durable polymer everolimus eluting stents at 1 year.
10. Meredith IT, Verheye S, Dubois CL, et al. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent. J Am Coll Cardiol 2012;59:1362-70.
11. Haude M, Lee SW, Worthley SG, et al. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv 2013;6:334-43.
12. Byrne RA, Kufner S, Tiroch K, et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 2009;95:1489-94.
13. Carrie D, Berland J, Verheye S, et al. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions. J Am Coll Cardiol 2012;59:1371-6.
14. Costa JR Jr., Abizaid A, Costa R, et al. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. J Am Coll Cardiol Intv 2009;2:422-7.
15. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910. ▶ First investigation of a fully bioresorbable drug eluting polymeric coronary scaffold.
16. Ormiston JA, Serruys PW, Onuma Y, et al. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study. Circ Cardiovasc Interv 2012;5:620-32.
17. Erbel R, Di Mario C, Bartunek J, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007;369:1869-75. (Pubitemid 46829357)
18. Haude M, Erbel R, Erne P, et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial. Lancet 2013;381:836-44. ▶ First investigation of a fully bioresorbable drug eluting metallic coronary scaffold.
19. van Geuns RJ, Tamburino C, Fajadet J, et al. Self-expanding versus balloon-expandable stents in acute myocardial infarction: results from the APPOSITION II study: self-expanding stents in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2012;5:1209-19.
20. Stone GW, Abizaid A, Silber S, et al. Prospective, randomized, multicenter evaluation of a polyethylene terephthalate micronet mesh-covered stent (MGuard) in ST-segment elevation myocardial infarction: the MASTER trial. J Am Coll Cardiol 2012 Sept 28. [Epub ahead of print]